By James Jardine
There's never been more buzz around the biopharma industry or more money being invested in it. The frenzy is being fueled by an ever-expanding array of new modalities like antibody-drug conjugates, mRNA, and other specialized innovations. Contract manufacturing is the engine driving biopharma's enormous growth, playing perhaps a more critical role than in any other sector of the pharmaceutical industry. Three biopharma contract manufacturing trends in particular are indicators of exciting industry developments, but they also reveal areas that are ripe for change.